Sucampo Pharmaceuticals, Inc. (SCMP) Earns “Buy” Rating from Maxim Group
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a report issued on Tuesday. They currently have a $23.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $21.00. Maxim Group’s target price indicates a potential upside of 114.95% from the company’s current price.
SCMP has been the subject of several other reports. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Jefferies Group LLC lowered their target price on Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating for the company in a research note on Thursday, May 4th. Finally, TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $17.63.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 2.39% during mid-day trading on Tuesday, reaching $10.70. The company’s stock had a trading volume of 627,562 shares. The firm has a 50-day moving average of $10.65 and a 200-day moving average of $10.72. The firm’s market capitalization is $494.28 million. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.06. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 EPS. Equities research analysts forecast that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.
In related news, insider Jones W. Bryan purchased 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average price of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares of the company’s stock, valued at approximately $49,820. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 4.13% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System boosted its position in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. bought a new position in shares of Sucampo Pharmaceuticals during the second quarter valued at approximately $116,000. Karp Capital Management Corp bought a new position in shares of Sucampo Pharmaceuticals during the first quarter valued at approximately $119,000. SG Americas Securities LLC boosted its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 631 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares during the last quarter. 58.20% of the stock is currently owned by institutional investors and hedge funds.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.